This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

James A. Schoenberger, MD; Marcia Testa, PhD; Adrienne D. Ross, PharmD; Wenda K. Brennan, RPh; James A. Bannon, PharmD

Arch Intern Med. 1990;150(2):301-306.

Abstract
• Successful long-term treatment of hypertension must include consideration of individual patients' life-styles interfaced with the potential for adverse drug events. In a postmarketing surveillance study, 30 515 patients received captopril monotherapy and were evaluated by 7792 physicians. Mean systolic and diastolic blood pressures were reduced 17 and 11 mm Hg, respectively. Mean diastolic blood pressure was reduced 10% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (16.5%) and severe (21.5%) hypertension. Captopril therapy was equally effective in all races (white, Hispanic, and black patients), age groups, and in isolated instances of systolic hypertension. Only 4.9% of patients reporting an adverse event required discontinuation of therapy. Headache (1.8%) and dizziness (1.6%) were the most frequently reported adverse events. Quality-of-life measures improved.

(Arch Intern Med. 1990;150:301-306)

Author Affiliations
From Rush-Presbyterian–St Luke's Medical Center, Chicago, Ill (Dr Schoenberger); Harvard School of Public Health and the Dana Farber Cancer Institute, Boston, Mass (Dr Testa); E. R. Squibb and Sons Inc, Princeton, NJ (Dr Ross); and the Philadelphia (Pa) Association for Clinical Trials (Ms Brennan and Dr Bannon).

Footnotes
Accepted for publication July 24,1989.

Reprint requests to Philadelphia Association for Clinical Trials, 150 Radnor-Chester Rd, Suite D200, St Davids, PA 19087 (Dr Bannon).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selected Factors That Influence Responses to Antihypertensives: Choosing Therapy for the Uncomplicated Patient
Carter et al.
Arch Fam Med 1994;3:528-535.
ABSTRACT  

Angiotensin-Converting Enzyme Inhibitors in Hypertension: A Dozen Years of Experience
Materson and Preston
Arch Intern Med 1994;154:513-523.
ABSTRACT  

Hypertension in Women: What is Really Known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine
Anastos et al.
ANN INTERN MED 1991;115:287-293.
ABSTRACT